152 related articles for article (PubMed ID: 11733359)
1. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.
Saramäki O; Willi N; Bratt O; Gasser TC; Koivisto P; Nupponen NN; Bubendorf L; Visakorpi T
Am J Pathol; 2001 Dec; 159(6):2089-94. PubMed ID: 11733359
[TBL] [Abstract][Full Text] [Related]
2. Mapping the amplification of EIF3S3 in breast and prostate cancer.
Nupponen NN; Isola J; Visakorpi T
Genes Chromosomes Cancer; 2000 Jun; 28(2):203-10. PubMed ID: 10825005
[TBL] [Abstract][Full Text] [Related]
3. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer.
Savinainen KJ; Linja MJ; Saramäki OR; Tammela TL; Chang GT; Brinkmann AO; Visakorpi T
Br J Cancer; 2004 Mar; 90(5):1041-6. PubMed ID: 14997205
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
Sato H; Minei S; Hachiya T; Yoshida T; Takimoto Y
Int J Urol; 2006 Jun; 13(6):761-6. PubMed ID: 16834657
[TBL] [Abstract][Full Text] [Related]
5. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer.
Nupponen NN; Porkka K; Kakkola L; Tanner M; Persson K; Borg A; Isola J; Visakorpi T
Am J Pathol; 1999 Jun; 154(6):1777-83. PubMed ID: 10362802
[TBL] [Abstract][Full Text] [Related]
6. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients.
Ribeiro FR; Henrique R; Martins AT; Jerónimo C; Teixeira MR
Eur Urol; 2007 Jul; 52(1):116-25. PubMed ID: 17070983
[TBL] [Abstract][Full Text] [Related]
7. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
[TBL] [Abstract][Full Text] [Related]
8. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas.
Okamoto H; Yasui K; Zhao C; Arii S; Inazawa J
Hepatology; 2003 Nov; 38(5):1242-9. PubMed ID: 14578863
[TBL] [Abstract][Full Text] [Related]
9. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer.
Tsuchiya N; Slezak JM; Lieber MM; Bergstralh EJ; Jenkins RB
Genes Chromosomes Cancer; 2002 Aug; 34(4):363-71. PubMed ID: 12112525
[TBL] [Abstract][Full Text] [Related]
11. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
Jenkins RB; Qian J; Lieber MM; Bostwick DG
Cancer Res; 1997 Feb; 57(3):524-31. PubMed ID: 9012485
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications.
Van Den Berg C; Guan XY; Von Hoff D; Jenkins R; Bittner ; Griffin C; Kallioniemi O; Visakorpi ; McGill ; Herath J
Clin Cancer Res; 1995 Jan; 1(1):11-8. PubMed ID: 9815882
[TBL] [Abstract][Full Text] [Related]
13. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
14. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer.
El Gammal AT; Brüchmann M; Zustin J; Isbarn H; Hellwinkel OJ; Köllermann J; Sauter G; Simon R; Wilczak W; Schwarz J; Bokemeyer C; Brümmendorf TH; Izbicki JR; Yekebas E; Fisch M; Huland H; Graefen M; Schlomm T
Clin Cancer Res; 2010 Jan; 16(1):56-64. PubMed ID: 20028754
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer.
Schlomm T; Kirstein P; Iwers L; Daniel B; Steuber T; Walz J; Chun FH; Haese A; Kollermann J; Graefen M; Huland H; Sauter G; Simon R; Erbersdobler A
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6579-84. PubMed ID: 18006757
[TBL] [Abstract][Full Text] [Related]
16. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
17. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor gene amplification and protein expression in recurrent prostate cancer.
Ford OH; Gregory CW; Kim D; Smitherman AB; Mohler JL
J Urol; 2003 Nov; 170(5):1817-21. PubMed ID: 14532783
[TBL] [Abstract][Full Text] [Related]
19. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer.
Mark HF; Samy M; Santoro K; Mark S; Feldman D
Exp Mol Pathol; 2000 Feb; 68(1):65-9. PubMed ID: 10640455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]